BCL11B, ETS1, GATA3, IL17R, NFIL3, and ID3 were upregulated in ILCs of MS patients, whereas TOX, RUNX3, ID2, and AHR were downregulated (Fig. 3B) potentially indicating loss of regulatory mechanisms. Here, TOX is linked to myeloid sarcoma.